The Iran war’s economic consequences are rippling into corners of the market that casual observers might not immediately connect to Middle East geopolitics.
One of Thursday’s more interesting stories was a pair of significant downgrades in the agricultural chemical space — a reminder that oil’s climb above $100 a barrel is not just an energy story, it’s an inflation story with supply chain implications across multiple industries.
Bank of America downgraded phosphate producer Mosaic to neutral from buy, cutting its price target to $27 and citing the surge in sulphur and ammonia input costs that have followed the spike in energy prices. Analyst Lucas Beaumont noted that while phosphate prices themselves are rising, the input cost pressure “will harm profitability.” Mosaic shares fell more than 4% on the session.
UBS moved in the same direction on Nutrien, downgrading the fertiliser giant to sell from neutral while slightly lifting its price target to $67 — implying a 12.5% downside from current levels. Nutrien’s stock has risen 25% in 2026 and 46% over the past year as supply disruption fears drove buyers to the sector. Beaumont’s argument is that the upside from a constrained supply environment is “already priced in,” meaning there is limited room for the shares to continue climbing without fresh catalysts. Nutrien fell more than 3%.
The pharmaceutical sector received rather different news. Robinhood, the retail brokerage, was initiated with a buy rating and an $88 price target by Jefferies, implying upside of around 21%. The firm described Robinhood as “levered to rising global retail participation,” pointing to its rapidly evolving product suite as a driver of increased revenue diversity and improved client retention. Separately, the Clear Secure travel biometrics company benefited from an unexpected catalyst — the DHS shutdown has extended TSA queues dramatically at major airports, prompting a surge in downloads of the Clear app. DA Davidson raised its price target to $65 from $54, citing a government shutdown that has “given Clear an opportunity to hit the ground running.” That kind of commentary — where bureaucratic dysfunction becomes an investment thesis — captures the bizarre nature of the current moment for equity investors.